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population. Median follow-up was 32.3 months. Median 
overall survival was 36.3 months (95 % confidence interval 
29.4–not reached). Subgroup analyses of overall survival 
suggested that the presence of brain metastases was a nega-
tive prognostic factor (median overall survival 22.7 months, 
95 % confidence interval 19.6–29.4). The impact on overall 
survival of using versus not using EGFR tyrosine kinase 
inhibitors in any line of treatment following disease pro-
gression was unclear (median 32.8 versus 36.3 months, 
respectively). No new safety issues were observed.
Conclusion In this survival update, single-agent erlotinib 
achieved a median overall survival of more than 3 years in 
patients with EGFR mutation-positive non-small-cell lung 
cancer.
Keywords Erlotinib · EGFR mutations · Non-small-cell 
lung cancer (NSCLC) · First line · Japanese patients · 
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Abstract 
Background In Japan, the clinical efficacy of erlotinib mono-
therapy in epidermal growth factor receptor (EGFR) muta-
tion-positive non-small-cell lung cancer was demonstrated in 
the phase II JO22903 trial, which reported a median progres-
sion-free survival of 11.8 months. Here we report final overall 
survival data from JO22903.
Methods JO22903 (JapicCTI-101085) was a single-arm, 
multicenter, phase II, open-label, non-randomized study of 
first-line erlotinib monotherapy in EGFR mutation-positive 
non-small-cell lung cancer. Eligible patients (≥20 years) 
with stage IIIB/IV or recurrent non-small-cell lung cancer 
and confirmed activating mutations of EGFR (exon 19 dele-
tion or L858R point mutation in exon 21) received oral erlo-
tinib 150 mg/day until disease progression or unacceptable 
toxicity. The primary endpoints were progression-free sur-
vival and safety; overall survival was a secondary endpoint.
Results At the final analysis, 102 patients were included in 
the modified intent-to-treat population and 103 in the safety 
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Introduction
In non-small-cell lung cancer (NSCLC), platinum doublet 
chemotherapy followed by second-line docetaxel mono-
therapy [1] or pemetrexed maintenance therapy following 
first-line platinum doublet chemotherapy [2] prolongs sur-
vival outcomes for patients with non-squamous NSCLC. 
Based on the efficacy of these treatments, it has been antic-
ipated that they will improve long-term survival of patients 
with epidermal growth factor receptor (EGFR) mutation-
positive NSCLC after the administration of EGFR tyrosine 
kinase inhibitors (TKIs).
The treatment of NSCLC has changed considerably in 
recent years. Following the discovery of the pivotal onco-
genic role of EGFR in unselected NSCLC [3, 4], the sub-
sequent development of EGFR TKIs provided new thera-
peutic options for the treatment of this disease. Greater 
understanding of tumor biology has since led to the dis-
covery that tumors with sensitizing EGFR mutations, par-
ticularly the somatic mutations in EGFR exons 19 and 21, 
respond favorably to EGFR TKIs compared with chemo-
therapy [5]. To reflect this, EGFR TKIs are recommended 
in clinical treatment guidelines for NSCLC.
Currently, gefitinib, erlotinib and afatinib are the only 
EGFR TKIs approved (US Food and Drug Administration, 
EU and Japan) for the treatment of EGFR mutation-posi-
tive NSCLC [6, 7]. These approvals were supported by data 
from several phase III clinical trials, which consistently 
reported that EGFR TKIs demonstrate significant progres-
sion-free survival (PFS) benefits compared with standard 
chemotherapy [8]. Median PFS with first-line gefitinib in 
EGFR mutation-positive NSCLC ranged between 9.6 and 
10.4 months in the pan-Asian IPASS study of gefitinib 
versus carboplatin/paclitaxel [9], the Japanese NEJ002 
study of gefitinib versus carboplatin-paclitaxel [10], and 
the WJTOG3405 study of gefitinib versus cisplatin/doc-
etaxel [11]. However, despite similar PFS results with gefi-
tinib in these studies, median OS was not consistent; the 
IPASS study reported a median OS of 21.6 months with 
gefitinib [9], whereas a longer median OS of 27.7 months 
was published in the NEJ002 study [10] and a median OS 
of 34.8 months was reported with gefitinib in the Japanese 
WJTOG3405 study [11].
Median OS with erlotinib in EGFR mutation-positive 
NSCLC was 22.7 months in the phase III OPTIMAL 
study of erlotinib versus gemcitabine plus carboplatin 
[12], and 22.9 months in the phase III EURTAC study of 
erlotinib versus chemotherapy [13]. However, as these 
two studies were conducted outside of Japan, the median 
OS with erlotinib in Japanese patients with EGFR muta-
tion-positive NSCLC is currently unknown. PFS for 
the single-agent erlotinib arm of the Japanese phase II 
JO25567 study was 9.7 months [14], which was simi-
lar to the 11.8 months median PFS (primary endpoint) 
reported for the phase II Japanese JO22903 study [15]. 
Here, we report final OS data with erlotinib monotherapy 
in the JO22903 study and present exploratory analyses 
of OS with respect to EGFR mutation subtype. We also 
evaluated whether OS was impacted by the use of post-
progression therapy.
Patients and methods
Study design and patients
JO22903 (JapicCTI-101085) was a phase II, single-arm, 
multicenter, open-label, non-randomized study of first-
line erlotinib monotherapy for the treatment of EGFR 
mutation-positive NSCLC. Full study design information 
has been previously published [15]. Briefly, the study 
was conducted at 25 centers in Japan. Patients were aged 
≥20 years with stage IIIB/IV or recurrent NSCLC, with 
no prior chemotherapy, Eastern Cooperative Oncology 
Group performance status of 0 or 1, and tumors harbor-
ing confirmed activating mutations of EGFR (exon 19 
deletions or L858R point mutations in exon 21). Patients 
were excluded if they had symptomatic brain metasta-
ses or if they had co-existence or history of interstitial 
lung disease (ILD). After discontinuation of the proto-
col treatment, patients were treated at the investigators 
discretion.
JO22903 was carried out in accordance with the Dec-
laration of Helsinki and also the Japanese Good Clinical 
Practice Guidelines. All patients provided written informed 
consent for study participation. The study protocol was 
approved by the local ethics committees.
Procedures
Full treatment procedures have been published previ-
ously [15]. Briefly, patients received oral erlotinib 150 mg/
day until disease progression (PD) or unacceptable toxic-
ity. Treatment was interrupted if ILD was suspected; for 
patients with confirmed ILD diagnosis, erlotinib was dis-
continued immediately. In cases of gastrointestinal perfo-
ration or any grade 4 adverse events (AEs), erlotinib was 
discontinued. Patients were screened for EGFR mutations 
in a local or central laboratory; EGFR mutation status was 
determined using Scorpion ARMS as described previously 
[15]. Lung and abdominal scans [computed tomography 
(CT)/magnetic resonance imaging (MRI)] were mandatory 
at baseline and during treatment until PD. Brain scans were 
mandatory at baseline (CT/MRI).
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Assessments
Tumor response was assessed by an independent review 
committee (IRC) using Response Evaluable Criteria in 
Solid Tumours (RECIST) version 1.0. The analysis of 
safety parameters was descriptive; safety was assessed 
according to the Medical Dictionary for Regulatory 
Activities (version 14.0) preferred terms and tabulated 
by grade. All patients who received at least one dose of 
study treatment were included in the safety population. 
A modified intent-to-treat (ITT) population was used 
for the efficacy analysis, which included all patients 
from the safety population without major protocol 
violations.
Fig. 1  Overall survival with 
a erlotinib monotherapy in the 
modified ITT population and  
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4 6 8 10 12 14 16 18 20
Months
22 24 26 28 30 32 34 36 38 40
n Events Median OS 1-year survival 2-year survival 30-month survival
  (95 % CI), months (95 % CI), % (95 % CI), % (95 % CI), %
102 50 36.3 92 69 57
  (29.4–NR) (87–97) (60–78) (47–67)
Follow-up (range): 1.6–38.5 months
EGFR   Median OS 1-year survival 2-year survival 30-month survival
mutation n Events (95 % CI), months (95 % CI), % (95 % CI), % (95 % CI), %
Exon 19 50 24 36.3 (29.9–NR) 98 (94–100) 74 (62–86) 62 (49–75)
deletion
L858R 52 26 34 (24.2–NR) 86 (77–96) 64 (51–77) 52 (38–66)
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Study endpoints
The co-primary endpoints were PFS in the modified ITT 
population as assessed by IRC according to RECIST ver-
sion 1.0, and safety. Secondary endpoints included OS and 
overall response rate.
Statistical analyses
Kaplan–Meier methodology was used to estimate median 
and 95 % confidence intervals (CI) for OS, and hazard 
ratios (HR) were estimated by the use of a Cox model. 




Patients were enrolled between April 2010 and October 
2010. Median follow-up was 32.2 months. At the time of 
this final analysis, 103 patients with confirmed EGFR 
mutations were included in the study. The safety population 
comprised all 103 patients whilst the modified ITT popu-
lation comprised 102 patients; one patient was excluded 
due to a major protocol violation (receipt of incorrect study 
medication) after enrolment.
Baseline patient characteristics have been previously 
published [15]. Briefly, the majority of patients were female 
(n = 70), with stage IV disease (n = 74), adenocarcinoma 
histology (n = 102), and were never-smokers (n = 59).
Efficacy analyses
In the modified ITT population at the updated data cut-
off, median OS with first-line erlotinib was 36.3 months 
(95 % CI: 29.4–not reached [NR]) based on the occurrence 
of 50 events. The 1-year survival rate was 92 % (95 % CI 
87–97), the 2-year survival rate was 69 % (95 % CI 60–78) 
and the 30-month survival rate was 57 % (95 % CI 47–67) 
(Fig. 1a). Univariate subgroup analyses showed shorter 
OS in patients with brain metastases at baseline (median 
OS 22.7 months, 95 % CI 19.6–29.4) and in those with a 
T790M EGFR mutation (median OS 20.0 months, 95 % CI 
15.8–24.2) (Table 1). When analyzed by the specific type 
of EGFR mutation, median OS was 36.3 months (95 % 
CI 29.9–NR) versus 34.0 months (95 % CI 24.2–NR), 
respectively, for patients with exon 19 deletion versus exon 
21 L858R point mutation (HR 0.77, 95 % CI 0.44–1.35, 
p = 0.3662) (Fig. 1b).
Four patients had PD with central nervous system (CNS) 
progression (Table 2; Fig. 2). Median OS was shorter 
in patients with CNS PD compared with those without 
(12.9 months [95 % CI 8.7–27.0] versus 36.3 months [95 % 
CI 22.9–NR]).
Table 1  Subgroup analysis of median overall survival
CI confidence interval, EGFR epidermal growth factor receptor, OS 
overall survival, NR not reached
Characteristics n Events Median OS (months) 95 % CI
Gender
 Female 69 33 36.3 29.4–NR
 Male 33 17 34.0 23.4–NR
Age
 <75 years 88 43 36.3 28.3–NR
 ≥75 years 14 7 31.2 18.6–NR
Stage
 IIIB/IV 77 43 31.2 26.5–NR
 Recurrence 25 7 NR 28.3–NR
Smoking status
 Yes 44 24 31.2 23.4–NR
 No 58 26 36.3 29.8–NR
EGFR mutation status
 Exon 19 deletion 50 24 36.3 29.8–NR
 L858R 50 24 34.0 22.7–NR
 L858R + T790M 2 2 20.0 15.8–24.2
Brain metastases
 Yes 21 16 22.7 19.6–29.4
 No 81 34 NR 32.4–NR
Table 2  Characteristics of patients who had CNS progression in erlotinib treatment
CNS central nervous system, del deletion, ECOG PS Eastern Cooperative Oncology Group performance status, EGFR epidermal growth factor 
receptor, F female, M male, OS overall survival, PD progressive disease, PFS progression-free survival
Number Age  
(years)




Baseline CNS  
metastases






1 50 M 1 19 del No 100 106 420
2 55 M 1 19 del Yes 150 335 823
3 55 F 0 L858R No 150 168 363
4 73 F 1 L858R Yes 150 80 266
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Post‑progression therapy
Following PD, the majority of patients went on to receive 
either platinum doublet chemotherapy, with or without 
bevacizumab (n = 60), further EGFR TKIs (n = 35), or 
single-agent chemotherapy (n = 39) (Table 3). In terms 
of second-line therapy, median OS was similar in patients 
who were treated with platinum doublet chemotherapy or 
other types of therapy [median OS 33.1 months (95 % CI 
27.0–NR) versus NR, respectively; Fig. 3a]. The use of fur-
ther EGFR TKIs in any line of treatment following PD also 
had no apparent impact on OS compared with not using 
an EGFR TKI as post-PD therapy in any line [median OS 
32.8 months (95 % CI 26.6–NR) versus 36.3 months (95 % 
CI 27.8–NR), respectively; Fig. 3b].
Safety
The safety profile of erlotinib did not change at this data 
update (Table 4) and was as previously reported [15]. The 
most common all grade treatment-related AEs were rash 
(82.5 %) and diarrhea (79.6 %), and the most common 
grade ≥3 treatment-related AEs were rash (14.6 %) and an 
increase in alanine aminotransferase (8.7 %).
Discussion
EGFR TKIs are the standard of care for the first-line treat-
ment of EGFR mutation-positive NSCLC [6, 7]. In Japan, 
the phase II, single-arm JO22903 study demonstrated effi-
cacy of erlotinib monotherapy in EGFR mutation-positive 
NSCLC, with a reported median PFS of 11.8 months [15]. 
In this updated analysis of the JO22903 study, the 30-month 
OS rate was 57 % (95 % CI 47–67) and median OS was 
36.3 months (95 % CI 29.4–NR). These findings represent 
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CNS progression at PD
No CNS progression at PD
CNS progression at PD n Events Median OS (months) 95 % CI
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Table 3  Therapies given upon disease progression (eight patients 
were receiving study treatment at data collection. Information was 
unavailable for ten patients)
EGFR TKI epidermal growth factor receptor tyrosine kinase inhibitor
Therapy (n) Second-line therapy All lines of treatment
Platinum doublet 46 60
 Without bevacizumab 31 41
 With bevacizumab 15 21
EGFR TKI 30 35
 Erlotinib 21 25
 Gefitinib 8 14
 Erlotinib + tivantinib 1 1
 Erlotinib +  
pemetrexed
0 1






 Docetaxel +  
bevacizumab
3 4
 Pemetrexed 3 15
 Docetaxel 1 24
 Pemetrexed +  
bevacizumab
0 1
Platinum doublet +  
EGFR TKI
1 2
 With erlotinib 1 2
Others 0 16
75Int J Clin Oncol (2017) 22:70–78 
1 3
a more favorable OS than observed in previous studies of 
first-line erlotinib in EGFR mutation-positive NSCLC out-
side Japan (median OS range 22.9–26.3 months [12, 13, 
16]), and are in line with results from prospective studies 
of other EGFR TKIs in Japanese populations (median OS 
range 27.7–34.8 months [10, 11]). Recently, a median OS 
of 46.9 months was reported for Japanese patients who 
received afatinib in the LUX-Lung 3 study [17], which 
was longer than that observed in the entire study popula-
tion [18]. Across these studies, the median PFS values 
observed in Japanese and global populations were very 
similar, at approximately 1 year [10–13, 16–18]. Thus, it 
seems that the current treatment landscape in Japan may be 
contributing to a longer OS compared with non-Japanese 
populations, and that OS in Japanese populations can rea-
sonably be expected to reach beyond 3 years.
Although patients with brain metastases have a poor 
prognosis, which is reflected by the shorter median OS for 
this subgroup, the findings of this present analysis suggest 
that erlotinib could be considered effective for patients with 
brain metastases, as only four patients had CNS progres-
sion. This finding is consistent with the phase II ASPI-
RATION study in Asian patients, which reported that just 
4.3 % of patients treated with post-PD erlotinib had new 
brain lesions [19]. This role for EGFR TKIs has also been 
observed in populations not restricted to Japanese or Asian 
patients [20–22]. A case series of 15 patients with NSCLC 
with EGFR mutations and CNS metastases who received 
Fig. 3  Overall survival by post-
PD therapy with a second-line 
platinum doublet chemotherapy 
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cerebrospinal fluid concentration (CSF) examinations dur-
ing EGFR TKI treatment provides further evidence to sup-
port this conclusion. In this case series, CNS response rate 
was 57 % with a favorable penetration rate of erlotinib 
in the CSF [23]. The penetration rate of erlotinib may be 
dependent on its affinity for p-glycoprotein, which pumps 
drugs out of the CNS. These findings suggest that erlo-
tinib has a favorable pharmacokinetic profile as a treatment 
option for patients with brain metastases.
Patients with an exon 19 deletion appeared to have 
longer OS in our analysis than those with exon 21 L858R 
EGFR mutation-positive NSCLC. This is similar to the 
results of a meta-analysis of seven trials (n = 1649), which 
concluded that patients with an exon 19 deletion had better 
efficacy outcomes than patients with exon 21 L858R EGFR 
mutation-positive NSCLC, regardless of which EGFR TKI 
they received [24]. These data suggest that patients with 
exon 19 deletion and exon 21 L858R EGFR mutation are 
clinically distinct populations that should be evaluated 
further.
In the present study, there was no apparent difference in 
OS according to subsequent treatments. Median OS was 
similar for patients who received EGFR TKIs as post-PD 
therapy (n = 36), which were mainly continuous erlotinib 
administration following RECIST PD (n = 21) (Table 3), 
and for those who did not. In contrast to our findings, in a 
retrospective study of patients with activating EGFR muta-
tions (n = 123) who were treated with EGFR TKIs, OS 
showed a trend in favor of continuing versus discontinuing 
EGFR TKI treatment following RECIST PD (33.0 versus 
21.2 months, respectively; p = 0.054) [25]. Furthermore, 
a retrospective clinical modeling study that evaluated the 
usefulness of EGFR TKI failure pattern for selecting sub-
sequent management, suggested that the efficacy of EGFR 
TKI continuation differed between patients with gradual 
progression, local progression, and dramatic progression 
[26]. Thus, one hypothesis for the inconsistency between 
studies is the difference in the EGFR TKI failure pattern. 
Meanwhile, in the present study, various EGFR TKIs were 
used as post-PD therapy (i.e., erlotinib beyond progression, 
erlotinib re-challenge after another treatment, and other 
therapies), which should be noted as one of the limitations. 
As effective post-PD therapy options are important for 
patients with disease recurrence, any benefit of EGFR TKI 
re-administration or continuation after PD requires further 
study.
At this updated analysis, no new safety signals for erlo-
tinib were observed; single-agent erlotinib was well toler-
ated and had an acceptable and manageable safety profile 
in EGFR mutation-positive NSCLC. The safety profile of 
erlotinib was also in line with previous studies of first-line 
erlotinib [13], with the most common AEs being rash and 
diarrhea.
In conclusion, single-agent erlotinib resulted in a 
median OS of 36.3 months in the first-line treatment of 
EGFR mutation-positive NSCLC. Subgroup analyses of 
OS suggested that the presence of brain metastases was 
a negative prognostic factor, as these patients had shorter 
median OS compared with other subgroups. No further 
differences in OS between specific EGFR subgroups were 
observed. Although many patients went on to receive addi-
tional EGFR TKI therapy following progression, there was 
no significant difference in median OS for patients who 
received EGFR TKI as post-PD therapy compared with 
those who did not. The findings of this single-arm study 
should be validated in randomized controlled trials.
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